DGX

Quest Diagnostics
D

DGX

Arincen63/100B

Quest Diagnostics return on equity (ROE)

Quest Diagnostics's return on equity is 15.32%: net income of 1.17B USD over the last twelve months on shareholders' equity of 7.63B USD.

Today
15.32%
Average, 5 years
16.66%
Low, 5 years
12.70%
High, 5 years
32.28%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 1.17B ÷ 7.63B = 15.32%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Quest Diagnostics's return on equity?

Net margin
9.0%
profit on each dollar of sales
Asset turnover
0.68×
sales on each dollar of assets
Equity multiplier
2.26×
assets on each dollar of equity
Return on equity
13.8%
FY2025
  • FY20259.0% × 0.68 × 2.26 = 13.8%
  • FY20248.8% × 0.61 × 2.38 = 12.9%
  • FY20239.2% × 0.66 × 2.22 = 13.5%
  • FY20229.6% × 0.77 × 2.18 = 16.1%
  • FY202118.5% × 0.79 × 2.11 = 31.0%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today15.32%1.17B7.63B
FY202531 Dec 202514.59%1.05B7.17B
FY202431 Dec 202413.59%921.00M6.78B
FY202331 Dec 202314.40%908.00M6.31B
FY202231 Dec 202217.22%1.02B5.89B
FY202131 Dec 202132.28%2.08B6.44B
FY202031 Dec 202022.18%1.50B6.76B
FY201931 Dec 201916.06%906.00M5.64B
FY201831 Dec 201815.11%788.00M5.22B
FY201731 Dec 201716.74%824.00M4.92B
FY201631 Dec 201615.04%696.00M4.63B
FY201531 Dec 201516.08%753.00M4.68B
FY201431 Dec 201413.76%592.00M4.30B
FY201331 Dec 201322.37%883.00M3.95B
FY201231 Dec 201214.22%592.10M4.16B
FY201131 Dec 201113.69%505.70M3.69B
FY201031 Dec 201018.77%757.00M4.03B
FY200931 Dec 200919.20%766.20M3.99B
FY200831 Dec 200816.13%581.50M3.60B
FY200731 Dec 200710.23%339.94M3.32B
FY200631 Dec 200619.42%586.42M3.02B
FY200531 Dec 200519.77%546.28M2.76B
FY200431 Dec 200421.81%499.20M2.29B
FY200331 Dec 200318.24%436.72M2.39B
FY200231 Dec 200218.21%322.15M1.77B
FY200131 Dec 200112.15%162.30M1.34B
FY200031 Dec 200010.17%104.95M1.03B
FY199931 Dec 1999-0.15%-1.30M863.10M
FY199831 Dec 19984.74%26.90M567.90M
FY199731 Dec 1997-4.12%-22.30M541.70M
FY199631 Dec 1996-116.19%-625.96M538.72M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Quest Diagnostics's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.